[Congressional Bills 119th Congress]
[From the U.S. Government Publishing Office]
[H.R. 4030 Introduced in House (IH)]

<DOC>






119th CONGRESS
  1st Session
                                H. R. 4030

 To amend the Public Health Service Act to authorize the Secretary of 
 Health and Human Services to address priority substance use disorder 
    and serious mental illness treatment needs through long-acting 
            injectable medications, and for other purposes.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                             June 17, 2025

 Mr. Dunn of Florida (for himself, Mr. Soto, and Mr. Bean of Florida) 
 introduced the following bill; which was referred to the Committee on 
                          Energy and Commerce

_______________________________________________________________________

                                 A BILL


 
 To amend the Public Health Service Act to authorize the Secretary of 
 Health and Human Services to address priority substance use disorder 
    and serious mental illness treatment needs through long-acting 
            injectable medications, and for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Treatment Continuity Act of 2025''.

SEC. 2. PRIORITY SUBSTANCE USE DISORDER AND SERIOUS MENTAL ILLNESS 
              TREATMENT NEEDS OF REGIONAL AND NATIONAL SIGNIFICANCE.

    (a) In General.--Section 509 of the Public Health Service Act (42 
U.S.C. 290bb-2) is amended--
            (1) in the section heading, by inserting ``and serious 
        mental illness'' after ``substance use disorder'';
            (2) in subsection (a)--
                    (A) in the matter preceding paragraph (1), by 
                inserting ``and serious mental illness'' after 
                ``substance use disorder''; and
                    (B) by striking paragraphs (1) through (3) and 
                inserting the following: ``
            ``(1) access to long-acting injectable medications that are 
        approved by the Food and Drug Administration for the treatment 
        of individuals with substance use disorders or serious mental 
        illness;
            ``(2) lab testing and supportive counseling for substance 
        use disorder and serious mental illness; and
            ``(3) training on the use of long-acting injectable 
        medications for the purposes described in paragraph (1), in 
        combination with associated clinical services such as 
        counseling.'';
            (3) in subsection (b)--
                    (A) in the subsection heading, by inserting ``and 
                Serious Mental Illness'' after ``Substance Use 
                Disorder''; and
                    (B) in paragraphs (1) and (2), by inserting ``and 
                serious mental illness'' after ``substance use 
                disorder'';
            (4) by striking subsections (d) and (e) and inserting the 
        following:
    ``(d) Annual Report to Congress.--Not later than 1 year after the 
date of enactment of the Treatment Continuity Act of 2025, and annually 
thereafter during the term of the program under this section, the 
Secretary shall transmit to Congress a report on the outcomes of such 
program, including completed or substantial progress toward treatment 
requirements based on clinician assessment.''; and
            (5) by redesignating subsection (f) as subsection (e).
    (b) Applicability.--The amendments made by this section shall apply 
to grants made under section 509 of the Public Health Service Act after 
the date of the enactment of this Act.
                                 <all>